News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cyclacel Limited (CYCC) Reports Phase 2 Sapacitabine Data in Acute Myeloid Leukemia and Myelodysplastic Syndromes at 2009 American Society of Hematology Annual Meeting


12/7/2009 8:48:59 AM

BERKELEY HEIGHTS, N.J., Dec. 5, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") announced today 1-year survival data from a Phase 2 randomized trial of oral sapacitabine capsules, a novel nucleoside analogue, in elderly patients with acute myeloid leukemia (AML) and separately interim response data in myelodysplastic syndromes (MDS). The data were reported in two poster presentations at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES